Genespire

genespire.com

genespire.com • Milan • Series B 2024 • Founded 2009

Milan • Series B 2024 • Founded 2009

Actively hiring

Biotechnology

Health Care

As featured in

markets.businessinsider.com

Overview

News

Salaries

Products

People

Growth

Offices

Financials

Overview

The Company At Genespire, we develop off-the-shelf gene therapies. Our proprietary immune shielded lentiviral vectors (ISLV) are designed to allow life-long production of a therapy directly from a patient's liver, offering a one-time treatment for adults and children with genetic diseases.

News

News YahooFinance 3 months ago

Genespire and SR-TIGET Show Durable Preclinical Efficacy of Liver-Directed Gene Therapy for Methylmalonic Acidemia

Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), has today announced the publication of preclinical data supporting the potential of its liver-directed immune-shielded lentiviral gene therapy

Report

Press release morningstar.com 3 months ago

Genespire and SR-TIGET Show Durable Preclinical Efficacy of Liver-Directed Gene Therapy for Methylmalonic Acidemia Read more

Report

News medindia.net 3 months ago

Genespire and SR-TIGET Show Durable Preclinical Efficacy of Liver-Directed Gene Therapy for Methylmalonic Acidemia Read more

Report

Press release The Manila Times 1 year ago

Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-humanin vivo liver-directed ISLV gene therapy for MMA

media618412

Report

News YahooFinance 2 years ago

Genespire raises €46.6 million ($52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

Genespire raises €46.6 million ($52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings to date Financing co-led by Sofinnova Partners, XGEN Venture

Report

News markets.businessinsider.com 6 years ago

Genespire and SR-Tiget announce strategic alliance for the development of transformative gene therapies for genetic diseases and disclose collaboration focus Read more

Report

Offices

Where the company hires and what each office is for

Cities

Hiring now

Countries

Milan Italy

Registered seat

Legal address

Via Borgogna 5, 20122 Milano – Italy

company site

Financials

Total raised

$50.3M

Latest round

Series B

Funding rounds

Round	Announced	Amount
Series B	2024	$50.3M	Details